| Literature DB >> 31423971 |
Maria D Van Kerkhove, Sadoof Alaswad, Abdullah Assiri, Ranawaka A P M Perera, Malik Peiris, Hassan E El Bushra, Abdulaziz A BinSaeed.
Abstract
To investigate a cluster of Middle East respiratory syndrome (MERS) cases in a women-only dormitory in Riyadh, Saudi Arabia, in October 2015, we collected epidemiologic information, nasopharyngeal/oropharyngeal swab samples, and blood samples from 828 residents during November 2015 and December 2015-January 2016. We found confirmed infection for 19 (8 by reverse transcription PCR and 11 by serologic testing). Infection attack rates varied (2.7%-32.3%) by dormitory building. No deaths occurred. Independent risk factors for infection were direct contact with a confirmed case-patient and sharing a room with a confirmed case-patient; a protective factor was having an air conditioner in the bedroom. For 9 women from whom a second serum sample was collected, antibodies remained detectable at titers >1:20 by pseudoparticle neutralization tests (n = 8) and 90% plaque-reduction neutralization tests (n = 2). In closed high-contact settings, MERS coronavirus was highly infectious and pathogenicity was relatively low.Entities:
Keywords: MERS-CoV; Middle East respiratory syndrome coronavirus; Riyadh; Saudi Arabia; human-to-human transmission; outbreak investigation; seroepidemiology; viruses
Mesh:
Year: 2019 PMID: 31423971 PMCID: PMC6759265 DOI: 10.3201/eid2510.190130
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Schematic of expatriate dormitory (the residence, buildings 1–12) and MERS-CoV infection attack rates (IARs), Riyadh, Saudi Arabia, 2015. Each building contained 2 villas on 3 floors. The distance between buildings is ≈5 m. During the initial investigation (October 2015), 8 residents were positive for MERS-CoV by PCR (indicated by black boxes); they lived in buildings 1B, 2A, and 5B. A vegetable garden separated buildings 3 and 10, and a convenience store (shop) separated buildings 6 and 7. IARs are shown as percentages inside each villa. MERS-CoV, Middle East respiratory syndrome coronavirus; PRNT, plaque-reduction neutralization test.
Demographic characteristics of patients with and without MERS-CoV infection, Riyadh, Saudi Arabia, 2015*
| Characteristics | All participants, no. (%), n = 828 | Case-patients, no. (%), n = 19† | Non–case-patients, no. (%), n = 809 |
|---|---|---|---|
| Sex | |||
| F | 814/814 (100)‡ | 19/19 (100)‡ | 795/795 (100)‡ |
| M | 0 | 0 | 0 |
*Median age (interquartile range): for all, 35.1 (26.6–41.3) years; for case-patients, 29.8 (28–37.2) years; for non–case-patients, 35.2 (29.6–41.4) years. CoV, coronavirus; MERS, Middle East respiratory syndrome; NA, not applicable. †Molecular or serologic evidence of MERS-CoV infection. ‡Denominator indicates the number of women who answered the question. §Included asthma, diabetes, heart disease, hypertension, and breast cancer.
Figure 2Epidemiologic curve for symptomatic laboratory-confirmed case-patients with Middle East respiratory syndrome coronavirus infection, Riyadh, Saudi Arabia, 2015. The curve includes only the 12 case-patients for whom symptom onset was reported, not the 7 case-patients for whom infection was serologically confirmed but no symptoms were reported in the preceding 4 weeks.
Characteristics of the MERS-CoV–positive participants identified from molecular and serologic assay results, Riyadh, Saudi Arabia, 2015*
| Age, y | Bldg no. | Signs/ symptoms† | Symptom onset date | RT-PCR‡ | Serologic test | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SI ELISA | ppNT | PRNT90 | Serologic test result§ | ||||||||||
| First sample | Second sample | First sample | Second sample | First sample | Second sample | ||||||||
| 23 | 1B | Yes | Oct 11 | + | 1.586 | 0.523 | 80 | 20 | 20 | 10 | + | ||
| 28 | 5B | Yes | Oct 14 | + | 2.225 | NA | 80 | NA | 40 | NA | + | ||
| 29 | 2A | Yes | Oct 13 | + | 1.181 | NA | 20 | NA | 10 | NA | + | ||
| 29 | 2A | Yes | Oct 14 | + | 4.57 | NA | 160 | NA | 80 | NA | + | ||
| 28 | 2A | Yes | Oct 1 | + | 3.154 | 2.741 | 160 | 160 | 40 | 40 | + | ||
| 26 | 2A | Yes | Oct 7 | + | 3.154 | NA | 160 | NA | 40 | NA | + | ||
| 39 | 2A | Yes | Sep 30 | + | 1.553 | NA | 40 | NA | 20 | NA | + | ||
| 53 | 2A | No | NS | + | 4.242 | NA | 160 | NA | 80 | NA | + | ||
| 41 | 1B | No | NS | NA | 1.311 | 0.33 | 20 | 10 | 10 | <10 | + | ||
| 37 | 2A | Yes | Oct 10 | – | 1.214 | 0.569 | 40 | 20 | 10 | <10 | + | ||
| 30 | 2A | Yes | Oct 22 | – | 0.759 | 0.605 | 20 | 20 | 0 | <10 | + | ||
| 24 | 2A | Yes | Oct 1 | – | 1.422 | NA | 80 | NA | 20 | NA | + | ||
| 32 | 2A | Yes | Sep 26 | – | 3.381 | 1.012 | 80 | 20 | 20 | 10 | + | ||
| 28 | 2A | Yes | Sep 19 | – | 1.999 | 1.654 | 40 | 40 | 10 | 20 | + | ||
| 30 | 1A | No | NS | NA | 3.295 | 1.496 | 40 | 20 | 10 | <10 | + | ||
| 36 | 2B | No | NS | – | 1.419 | NA | 20 | NA | 20 | NA | + | ||
| 42 | 7A | No | NS | NA | 0.576 | NA | 01:10 | NA | 20 | NA | + | ||
| 37 | 10A | No | NS | NA | 1.115 | NA | 0.097222 | NA | 80 | NA | + | ||
| 45 | 2A | No | NS | – | 1.111 | 0.563 | 20 | 20 | <10 | <10 | + | ||
*First samples collected November 13, 2015; second samples collected March 22, 2015. Bldg, building; CoV, coronavirus; MERS, Middle East respiratory syndrome; NA, not available/not collected; NS, no signs/symptoms reported; ppNT, pseudoparticle neutralization test; PRNT90, 90% plaque-reduction neutralization test; RT-PCR, reverse transcription PCR; +, positive; –, negative. †Self-reported or observed signs/symptoms in the 14 d before epidemiologic interview. ‡According to World Health Organization criteria (http://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing). §Serologic test result was defined as positive if either PRNT90 or ppNT titers were >20. S1 ELISA results are shown for information only; they were not used in designating infection status.
Bivariate analyses of reported exposures to known MERS patient, including overall cohort, Riyadh, Saudi Arabia, 2015*
| Reported exposure | Case-patients, no. (%), n = 19 | Non–case-patients, no. (%), n = 809 | p value† | RR (95% CI) |
|---|---|---|---|---|
| Direct contact with known (symptomatic) MERS-CoV case-patient | 11 (57.9) | 43 (5.3) | <0.001 | 10.9 (6.7–17.6) |
| Shared bedroom with known case-patient | 6 (31.6) | 10 (1.2) | <0.001 | 25.5 (10.3–63.1) |
| Shared kitchen with known case-patient | 4 (21.1) | 11 (1.4) | <0.001 | 15.5 (5.4–44.2) |
| Shared bathroom with known case-patient | 6 (31.6) | 10 (1.2) | <0.001 | 25.5(10.3–63.1) |
| Shared meal with known case-patient | 5 (26.3) | 11 (1.4) | <0.001 | 19.4 (7.5–50.3) |
| Shared transportation to/from place of employment with known case-patient | 5 (26.3) | 18 (2.2) | <0.001 | 11.8 (4.9–28.5) |
| Reported nondirect contact with case-patient‡ | 4 (21.1) | 11 (1.4) | <0.001 | 15.5 (5.4–44.2) |
*CoV, coronavirus; MERS, Middle East respiratory syndrome; RR, risk ratio. †By χ2 test. ‡No physical contact, nonphysical contact (including talk to the known case-patient).